| PEMOA28 | Pharmacologic intervention to reduce chronic inflammation in people with HIV | Poster exhibition | Immunotherapy (including broadly neutralizing antibodies) |
| PEMOA29 | In vitro release and in vivo pharmacokinetics of antiretroviral drugs from ultra-long-acting polymeric implants: towards better outcomes for HIV prevention and treatment | Poster exhibition | ARVs, small molecules and immunomodulating agents - pharmacodynamics and pharmacokinetics |
| PEMOA30 | Persistent AP-1-induced immune activation during early SARS-CoV-2 infection revealed by simultaneous single-cell epigenetic and gene expression profiling | Poster exhibition | Immune responses to SARS-Cov2 |
| PEMOA31 | HIV skews the B cell response to SARS-CoV-2 toward extrafollicular maturation | Poster exhibition | Immune responses to SARS-Cov2 |
| PEMOA32 | The impact of delta and omicron variants in the T-cell response to mRNA vaccination in people living with HIV | Poster exhibition | Immune responses to SARS-Cov2 |
| PEMOA33 | Serological responses to SARS-CoV2 vaccination in people with HIV: the SCAPE-HIV study | Poster exhibition | SARS-Cov2 vaccines |
| PEMOA34 | Seroprevalence of cross-reactive anti-SARS-CoV-2 antibodies in pre-COVID-19 samples collected from Cameroonian women during pregnancy and at delivery | Poster exhibition | Immune responses to SARS-Cov2 |
| PEMOA35 | Side-by-side comparison of SARS-CoV-2 neutralizing antibody responses after various COVID-19 vaccine regimens | Poster exhibition | SARS-Cov2 vaccines |
| PEMOA36 | Immunogenicity of the BNT 162b2 mRNA vaccine against COVID-19 variants in people living with HIV on antiretroviral therapy in Malaysia | Poster exhibition | SARS-Cov2 vaccines |
| PEMOA37 | Vaccine scheme, age and previous COVID-19 predict humoral response to SARS-CoV-2 vaccination in HIV-infected indivudals | Poster exhibition | SARS-Cov2 vaccines |